News & Updates

Using beta-blockers early can prevent 1-year mortality in patients with acute myocardial injury (AMI), reveals a recent study.

Effective antiviral therapy is crucial for achieving sustained viral clearance and improving outcomes in patients with COVID-19, particularly among immunocompromised individuals.

At the recent ESCMID Global 2025 in Vienna, Austria, Ruth Mokgokong, a pharmacologist at Pfizer, UK, presented findings from the EPIC-IC trial, highlighting the benefits of an extended nirmatrelvir-ritonavir regimen in severely immunocompromised patients with symptomatic COVID-19.

Cannabis use increases the risk of major adverse cardiovascular events (MACE), as shown in a robust meta-analysis, raising serious questions about the assumptions that cannabis use poses little cardiovascular (CV) risk among users.

Even in 2025, COVID-19 remains a significant global health concern. At a Pfizer-sponsored series of integrated symposia held during the ESCMID Global Congress in Vienna, Austria, leading experts presented the latest data and real-world experiences spanning the COVID-19 care continuum—from vaccination strategies to early antiviral treatment.

A Singapore study has found that patients referred for kidney disease are predominantly Malays, who tend to have higher metabolic disease burden, miss their appointments, and be referred at lower estimated glomerular filtration rate (eGFR).

The majority of subcutaneous implantable cardioverter defibrillator (S-ICD) recipients may safely forgo defibrillation testing (DT) during implantation, suggests a study. However, selective DT may be considered in those at higher risk.